Emmert, Alexander

[["dc.bibliographiccitation.artnumber","e16712"],["dc.bibliographiccitation.issue","31"],["dc.bibliographiccitation.journal","Medicine"],["dc.bibliographiccitation.volume","98"],["dc.contributor.author","Buentzel, Judith"],["dc.contributor.author","Yao, Sha"],["dc.contributor.author","Elakad, Omar"],["dc.contributor.author","Lois, Anna-Maria"],["dc.contributor.author","Brünies, Jana"],["dc.contributor.author","König, Julia"],["dc.contributor.author","Hinterthaner, Marc"],["dc.contributor.author","Danner, Bernhard C."],["dc.contributor.author","Ströbel, Philipp"],["dc.contributor.author","Emmert, Alexander"],["dc.contributor.author","Bohnenberger, Hanibal"],["dc.date.accessioned","2019-08-09T06:40:34Z"],["dc.date.available","2019-08-09T06:40:34Z"],["dc.date.issued","2019"],["dc.description.abstract","Molecular characterization of lung cancer specimens after radical surgery offers additional prognostic information and may help to guide adjuvant therapeutic procedures. The transcriptional regulators alpha thalassemia/mental retardation X-linked (ATRX) and death domain-associated protein (DAXX) have recently been described in different cancer entities as a useful prognostic biomarker. This study was initiated to explore their protein expression patterns and prognostic value in patients with operable lung cancer disease.The protein abundance (in the following text also named protein expression) of ATRX and DAXX were analyzed by immunohistochemistry in 194 samples of squamous cell lung carcinoma (SQCLC), 111 samples of pulmonary adenocarcinoma (AC) and 40 samples of small cell lung cancer (SCLC). The protein levels of ATRX and DAXX were correlated with clinicopathological characteristics and patient outcome.ATRX showed strong protein expression in 16.2% of AC, 11.9% of SQCLC, and 42.5% of SCLC. DAXX was highly expressed in 54.9% of AC, 76.2% of SQCLC, and 82.5% of SCLC. Immunostaining of both ATRX and DAXX were seen in 14.4% of AC, 11.3% of SQCLC, and 42.5% of SCLC. High protein expression of ATRX was a favorable prognostic marker for patients with AC (hazard ratio 0.38, P = .02). Sub-group analyses showed a significant correlation between ATRX and the clinical stage of SQCLC and SCLC. Histological grading and ATRX were also significantly associated in cases of SQCLC.The presence of ATRX and DAXX are correlated with lung cancer histology. Strong ATRX protein expression is associated with a significantly longer overall survival in patients with AC."],["dc.description.sponsorship","Open-Access-Publikationafonds 2019"],["dc.identifier.doi","10.1097/MD.0000000000016712"],["dc.identifier.pmid","31374064"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/16343"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/62353"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.relation.eissn","1536-5964"],["dc.relation.issn","0025-7974"],["dc.rights","CC BY-NC-ND 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by-nc-nd/4.0"],["dc.title","Expression and prognostic impact of alpha thalassemia/mental retardation X-linked and death domain-associated protein in human lung cancer"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","19"],["dc.bibliographiccitation.journal","Cancer Research"],["dc.bibliographiccitation.volume","74"],["dc.contributor.author","Bohnenberger, Hanibal"],["dc.contributor.author","Stroebel, Philipp"],["dc.contributor.author","Henric-Petri, Hannah"],["dc.contributor.author","Lenz, Christof"],["dc.contributor.author","Emmert, Alexander"],["dc.contributor.author","Bremmer, Felix"],["dc.contributor.author","Strecker, Jasmin"],["dc.contributor.author","Holland, Rainer"],["dc.contributor.author","Hinterthaner, Marc"],["dc.contributor.author","Corso, Jasmin"],["dc.contributor.author","Wagner, Sebastian"],["dc.contributor.author","Kueffer, Stefan"],["dc.contributor.author","Sebastian, Martin"],["dc.contributor.author","Bergmann, Lothar"],["dc.contributor.author","Danner, Bernd"],["dc.contributor.author","Schoendube, Friedrich Albert"],["dc.contributor.author","Serve, Hubert"],["dc.contributor.author","Urlaub, Henning"],["dc.contributor.author","Oellerich, Thomas"],["dc.date.accessioned","2018-11-07T09:33:49Z"],["dc.date.available","2018-11-07T09:33:49Z"],["dc.date.issued","2014"],["dc.identifier.doi","10.1158/1538-7445.AM2014-2487"],["dc.identifier.isi","000349906903219"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/32050"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Amer Assoc Cancer Research"],["dc.publisher.place","Philadelphia"],["dc.relation.conference","105th Annual Meeting of the American-Association-for-Cancer-Research (AACR)"],["dc.relation.eventlocation","San Diego, CA"],["dc.relation.issn","1538-7445"],["dc.relation.issn","0008-5472"],["dc.title","Comprehensive quantitative proteomic profiling of lung cancers reveals novel biomarkers and potential drug targets"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","21"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Cancer Cell"],["dc.bibliographiccitation.lastpage","36.e13"],["dc.bibliographiccitation.volume","37"],["dc.contributor.author","Goveia, Jermaine"],["dc.contributor.author","Rohlenova, Katerina"],["dc.contributor.author","Taverna, Federico"],["dc.contributor.author","Treps, Lucas"],["dc.contributor.author","Conradi, Lena-Christin"],["dc.contributor.author","Pircher, Andreas"],["dc.contributor.author","Geldhof, Vincent"],["dc.contributor.author","de Rooij, Laura P.M.H."],["dc.contributor.author","Kalucka, Joanna"],["dc.contributor.author","Sokol, Liliana"],["dc.contributor.author","García-Caballero, Melissa"],["dc.contributor.author","Zheng, Yingfeng"],["dc.contributor.author","Qian, Junbin"],["dc.contributor.author","Teuwen, Laure-Anne"],["dc.contributor.author","Khan, Shawez"],["dc.contributor.author","Boeckx, Bram"],["dc.contributor.author","Wauters, Els"],["dc.contributor.author","Decaluwé, Herbert"],["dc.contributor.author","De Leyn, Paul"],["dc.contributor.author","Vansteenkiste, Johan"],["dc.contributor.author","Weynand, Birgit"],["dc.contributor.author","Sagaert, Xavier"],["dc.contributor.author","Verbeken, Erik"],["dc.contributor.author","Wolthuis, Albert"],["dc.contributor.author","Topal, Baki"],["dc.contributor.author","Everaerts, Wouter"],["dc.contributor.author","Bohnenberger, Hanibal"],["dc.contributor.author","Emmert, Alexander"],["dc.contributor.author","Panovska, Dena"],["dc.contributor.author","De Smet, Frederik"],["dc.contributor.author","Staal, Frank J.T."],["dc.contributor.author","Mclaughlin, Rene J."],["dc.contributor.author","Impens, Francis"],["dc.contributor.author","Lagani, Vincenzo"],["dc.contributor.author","Vinckier, Stefan"],["dc.contributor.author","Mazzone, Massimiliano"],["dc.contributor.author","Schoonjans, Luc"],["dc.contributor.author","Dewerchin, Mieke"],["dc.contributor.author","Eelen, Guy"],["dc.contributor.author","Karakach, Tobias K."],["dc.contributor.author","Yang, Huanming"],["dc.contributor.author","Wang, Jian"],["dc.contributor.author","Bolund, Lars"],["dc.contributor.author","Lin, Lin"],["dc.contributor.author","Thienpont, Bernard"],["dc.contributor.author","Li, Xuri"],["dc.contributor.author","Lambrechts, Diether"],["dc.contributor.author","Luo, Yonglun"],["dc.contributor.author","Carmeliet, Peter"],["dc.date.accessioned","2020-12-10T14:22:57Z"],["dc.date.available","2020-12-10T14:22:57Z"],["dc.date.issued","2020"],["dc.identifier.doi","10.1016/j.ccell.2019.12.001"],["dc.identifier.issn","1535-6108"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/71785"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","An Integrated Gene Expression Landscape Profiling Approach to Identify Lung Tumor Endothelial Cell Heterogeneity and Angiogenic Candidates"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","704"],["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","Histopathology"],["dc.bibliographiccitation.lastpage","710"],["dc.bibliographiccitation.volume","70"],["dc.contributor.author","Buerger, Tobias"],["dc.contributor.author","Schaefer, Inga-Marie"],["dc.contributor.author","Kueffer, Stefan"],["dc.contributor.author","Bohnenberger, Hanibal"],["dc.contributor.author","Reuter-Jessen, Kirsten"],["dc.contributor.author","Chan, John Kwok-Cheung"],["dc.contributor.author","Emmert, Alexander"],["dc.contributor.author","Hinterthaner, Marc"],["dc.contributor.author","Marx, Alexander"],["dc.contributor.author","Stroebel, Philipp"],["dc.date.accessioned","2018-11-07T10:25:44Z"],["dc.date.available","2018-11-07T10:25:44Z"],["dc.date.issued","2017"],["dc.description.abstract","AimsThe vast majority of type A thymomas are diagnosed in tumour stages 1 or 2, and metastatic cases are exceedingly rare. The histological and genetic features of such metastatic type A thymomas have not been described in detail. Methods and resultsFive metastatic type A thymomas in tumour stage Masaoka IVb that had been reviewed by a panel of expert pathologists were analysed using comparative genomic hybridization (CGH). Cases 1, 2 and 3 showed the prototypical morphology of type A thymomas with mainly solid growth patterns. These cases displayed only very subtle nuclear irregularities and slight nuclear crowding, but no other atypical features. Mitoses were absent. Cases 3 and 4, in contrast, had a distinctly atypical morphology. CGH revealed partially recurrent alterations in four cases (with and without atypical morphology), including gains on chromosome 1q (one case), 17q (two cases), chromosome 19 (three cases) and 22q (one case) and losses on chromosome 17p (two cases) and 22q (one case). ConclusionRare metastatic type A thymomas, both with typical and atypical' histological features, show partially recurrent genomic alterations that differ from the much more frequent localized and indolent tumours. The fact that these alterations were recurring points to a link between clinical behaviour and molecular features. Our findings may have implications for the management and treatment of such tumours."],["dc.identifier.doi","10.1111/his.13138"],["dc.identifier.isi","000397588600003"],["dc.identifier.pmid","27926794"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/42916"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","PUB_WoS_Import"],["dc.publisher","Wiley"],["dc.relation.issn","1365-2559"],["dc.relation.issn","0309-0167"],["dc.title","Metastatic type A thymoma: morphological and genetic correlation"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1841"],["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","The Annals of Thoracic Surgery"],["dc.bibliographiccitation.lastpage","1843"],["dc.bibliographiccitation.volume","98"],["dc.contributor.author","Emmert, Alexander"],["dc.contributor.author","Jebran, Ahmad Fawad"],["dc.contributor.author","Schmidt, Karsten"],["dc.contributor.author","Hinterthaner, Marc"],["dc.contributor.author","Bohnenberger, Hanibal"],["dc.contributor.author","Bähr, Mathias"],["dc.contributor.author","Schoendube, Friedrich A."],["dc.contributor.author","Danner, Bernhard C."],["dc.date.accessioned","2017-09-07T11:45:25Z"],["dc.date.available","2017-09-07T11:45:25Z"],["dc.date.issued","2014"],["dc.description.abstract","This clinical report deals with a giant true pulmonary venous aneurysm, which was partially thrombosed. The overall incidence of pulmonary venous aneurysms is unknown, and they are reported only occasionally. We present the case of a previously healthy man with acute onset of ischemic cerebral stroke. The cause was a thrombus in a huge aneurysm of the left superior pulmonary vein. The patient subsequently underwent uncomplicated therapy for stroke, including thrombolysis followed by excision of the giant pulmonary venous aneurysm. As curative therapy we recommend complete resection of this rare entity. (C) 2014 by The Society of Thoracic Surgeons"],["dc.identifier.doi","10.1016/j.athoracsur.2013.12.087"],["dc.identifier.gro","3142027"],["dc.identifier.isi","000344746600085"],["dc.identifier.pmid","25441803"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/3734"],["dc.notes.intern","WoS Import 2017-03-10"],["dc.notes.status","final"],["dc.notes.submitter","PUB_WoS_Import"],["dc.publisher","Elsevier Science Inc"],["dc.relation.eissn","1552-6259"],["dc.relation.issn","0003-4975"],["dc.title","Aneurysm of the Pulmonary Vein: An Unusual Cause of Stroke"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.subtype","letter_note"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","4603"],["dc.bibliographiccitation.issue","9"],["dc.bibliographiccitation.journal","Anticancer Research"],["dc.bibliographiccitation.lastpage","4612"],["dc.bibliographiccitation.volume","39"],["dc.contributor.author","BUENTZEL, JUDITH"],["dc.contributor.author","HEINZ, JUDITH"],["dc.contributor.author","BLECKMANN, ANNALEN"],["dc.contributor.author","BAUER, CHRISTOPH"],["dc.contributor.author","RÖVER, CHRISTIAN"],["dc.contributor.author","BOHNENBERGER, HANIBAL"],["dc.contributor.author","SAHA, SHEKHAR"],["dc.contributor.author","HINTERTHANER, MARC"],["dc.contributor.author","BARAKI, HASSINA"],["dc.contributor.author","KUTSCHKA, INGO"],["dc.contributor.author","EMMERT, ALEXANDER"],["dc.date.accessioned","2020-12-10T18:43:04Z"],["dc.date.available","2020-12-10T18:43:04Z"],["dc.date.issued","2019"],["dc.identifier.doi","10.21873/anticanres.13640"],["dc.identifier.eissn","1791-7530"],["dc.identifier.issn","0250-7005"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/78183"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Sarcopenia as Prognostic Factor in Lung Cancer Patients: A Systematic Review and Meta-analysis"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","e85"],["dc.bibliographiccitation.firstpage","1"],["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","International Journal of Surgery. Oncology"],["dc.bibliographiccitation.lastpage","5"],["dc.bibliographiccitation.volume","5"],["dc.contributor.author","Saha, Shekhar"],["dc.contributor.author","Yao, Sha"],["dc.contributor.author","Elakad, Omar"],["dc.contributor.author","Lois, Anna-Maria"],["dc.contributor.author","Henric-Petri, Hannah"],["dc.contributor.author","Buentzel, Judith"],["dc.contributor.author","Hinterthaner, Marc"],["dc.contributor.author","Danner, Bernhard C."],["dc.contributor.author","Ströbel, Philipp"],["dc.contributor.author","Emmert, Alexander"],["dc.contributor.author","Bohnenberger, Hanibal"],["dc.date.accessioned","2020-06-09T11:55:48Z"],["dc.date.accessioned","2021-10-27T13:22:15Z"],["dc.date.available","2020-06-09T11:55:48Z"],["dc.date.available","2021-10-27T13:22:15Z"],["dc.date.issued","2020"],["dc.description.abstract","Background: UDP-glucose-6-dehydrogenase (UGDH) plays an important role in the production of hyaluronic acid, an extracellular matrix component that is responsible for the promotion of normal cellular growth and migration. Increased levels of UGDH have been linked to the progression of epithelial cancers, such as those of the breast, colon and prostate. Therefore we aimed to analyze if the expression level of UGDH does also influence patients survival of lung cancer patients. Methods: UGDH expression levels were analyzed by immunohistochemistry in 96 samples of pulmonary adenocarcinoma (AC), 84 cases of squamous cell lung carcinoma (SQCLC) and 33 samples of small cell lung cancer (SCLC) and correlated with clinicopathologic characteristics and patient outcome. Results: UGDH was expressed in 62.5% cases of AC, 70.2% cases of SQCLC, and 48.5% cases of SCLC. In AC, expression of UGDH was significantly associated with lymph node metastasis and worse overall survival of the affected patients. However, UGDH expression had no significant correlation to prognosis in SQCLC or SCLC patients. Conclusions: In our study, expression of UGDH was associated with worse prognosis of patients with pulmonary adenocarcinoma so that expression of UGDH might help to guide treatment decisions. Furthermore, UGDH might present a potential novel drug target in AC as it displays inhibitable catalytic activity."],["dc.description.sponsorship","Open-Access-Publikationsfonds 2020"],["dc.identifier.doi","10.1097/IJ9.0000000000000085"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/17377"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/92078"],["dc.language.iso","en"],["dc.notes.intern","Migrated from goescholar"],["dc.relation.issn","2471-3864"],["dc.relation.orgunit","Universitätsmedizin Göttingen"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.subject.ddc","610"],["dc.title","UDP-glucose 6-dehydrogenase expression as a predictor of survival in patients with pulmonary adenocarcinoma"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","47"],["dc.bibliographiccitation.issue","04"],["dc.bibliographiccitation.journal","Open Journal of Thoracic Surgery"],["dc.bibliographiccitation.lastpage","56"],["dc.bibliographiccitation.volume","06"],["dc.contributor.author","Emmert, Alexander"],["dc.contributor.author","Oellerich, Angelika"],["dc.contributor.author","Füzesi, Laszlo"],["dc.contributor.author","Beushausen, Regina Waldmann-"],["dc.contributor.author","Schöndube, Friedrich A."],["dc.contributor.author","Bohnenberger, Hanibal"],["dc.contributor.author","Danner, Bernhard C."],["dc.date.accessioned","2019-07-09T11:43:03Z"],["dc.date.available","2019-07-09T11:43:03Z"],["dc.date.issued","2016"],["dc.description.abstract","Pigment epithelium-derived factor (PEDF), a potent antiangiogenesis agent, is a multifunctional protein with important roles in regulation of inflammation and angiogenesis. It has recently attracted attention for targeting tumor cells in several types of tumors. PECAM-1 is an integral membrane protein, a cell adhesion molecule with proangiogenic activity and plays an important role in the process of angiogenesis. The correlation between proangiogenic activity PECAM-1 and antiangiogenic activity PEDF in Non-Small-Cell-Lung Cancer has not been reported. The present study was designed to evaluate using immunohistochemical techniques and multivariate analysis the interplay between PECAM-1 and PEDF in NSCLC, especially in adenocarcinoma and in squamous cell carcinoma stage IA-IIIB. Analyzing the mixed study collectively (n = 69), there was no significant correlation (p = 0.553) between PECAM-1 signal and PEDF area. Only including patients with adenocarcinoma (Figure 2), we found a positive correlation between PECAM-1 signal and PEDF area (p = 0.025). In patients with squamous cell carcinoma, we did not find a significant correlation between PECAM-1 signal and PEDF area (p = 0.530). In patients with squamous cell carcinoma, PECAM-1 and PEDF show a significant different expression pattern, measured via staining intensity (p = 0.013). These results might support the hypothesis that squamous cell carcinomas heavily rely on angiogenic processes."],["dc.identifier.doi","10.4236/ojts.2016.64007"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/14092"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/58813"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.relation.issn","2164-3067"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.title","Interplay between Platelet Endothelial Cell Adhesion Molecule-1 and Pigment Epithelium-Derived Factor in Non-Small-Cell-Lung Cancer"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","9"],["dc.bibliographiccitation.journal","Journal of Thoracic Oncology"],["dc.bibliographiccitation.volume","10"],["dc.contributor.author","Bohnenberger, Hanibal"],["dc.contributor.author","Yepes, Diego"],["dc.contributor.author","Pan, Kuan-Ting"],["dc.contributor.author","Emmert, Alexander"],["dc.contributor.author","Henric-Petri, Hannah"],["dc.contributor.author","Bremmer, Felix"],["dc.contributor.author","Strecker, Jasmin"],["dc.contributor.author","Lois, Anna-Maria"],["dc.contributor.author","Fischer, Lucas"],["dc.contributor.author","Kueffer, Stefan"],["dc.contributor.author","Hinterthaner, Marc"],["dc.contributor.author","Wolff, Hendrik"],["dc.contributor.author","Canis, Martin"],["dc.contributor.author","Sebastian, Martin"],["dc.contributor.author","Danner, Bernd"],["dc.contributor.author","Stroebel, Philipp"],["dc.contributor.author","Serve, Hubert"],["dc.contributor.author","Urlaub, Henning"],["dc.contributor.author","Oellerich, Thomas"],["dc.date.accessioned","2018-11-07T09:51:51Z"],["dc.date.available","2018-11-07T09:51:51Z"],["dc.date.issued","2015"],["dc.format.extent","S293"],["dc.identifier.isi","000370365101087"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/35995"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Elsevier Science Inc"],["dc.publisher.place","New york"],["dc.relation.issn","1556-1380"],["dc.relation.issn","1556-0864"],["dc.title","Proteomic Profiling of Pulmonary Cancer with Squamous Cell Histology"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","21"],["dc.bibliographiccitation.issue","03"],["dc.bibliographiccitation.journal","Advances in Lung Cancer"],["dc.bibliographiccitation.lastpage","29"],["dc.bibliographiccitation.volume","05"],["dc.contributor.author","Emmert, Alexander"],["dc.contributor.author","Oellerich, Angelika"],["dc.contributor.author","Füzesi, Laszlo"],["dc.contributor.author","Waldmann-Beushausen, Regina"],["dc.contributor.author","Bohnenberger, Hanibal"],["dc.contributor.author","Schöndube, Friedrich A."],["dc.contributor.author","Danner, Bernhard C."],["dc.date.accessioned","2019-07-09T11:43:03Z"],["dc.date.available","2019-07-09T11:43:03Z"],["dc.date.issued","2016"],["dc.description.abstract","Non-small cell lung cancer (NSCLC) is the primary cause of cancer related death worldwide. After resection of early stage NSCLC, the benefit of adjuvant chemotherapy for patient survival still remains unclear and investigations for further risk stratification are needed for an improved treatment decision. Microvessel density (MVD) influences both the nutrition of the cancer and the access to the bloodstream for the development of distant metastasis. The aim of this study was to examine the prognostic significance of microvessel density by CD31 staining in patients with resected stage IA-IIIB NSCLC. We used immunohistochemistry (IHC) of CD31 to examine the microvessel density in a cohort of 69 patients who had undergone radical resection for NSCLC. Correlation of IHC values and standard clinicopathologic parameters was analyzed as well as influence on long term survival. Survival analysis revealed a significant better overall survival for patients with higher median microvessel density (log rank p = 0.031) independent of clinicopathologic parameters. Regarding primary cancer related death, the survival was again significantly longer in patients with high CD31 count (log rank p = 0.036). A higher microvessel density was a strong predictor for a longer tumor related survival and could be used for therapeutic decisions of adjuvant chemotherapy after resection of early stage NSCLC."],["dc.identifier.doi","10.4236/alc.2016.53003"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/14089"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/58810"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.relation.issn","2169-2726"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.title","Prognostic Significance of CD31 Expression in Patients with Non-Small-Cell-Lung Cancer"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]